Back to Search Start Over

Identification of Methylation Signatures and Rules for Sarcoma Subtypes by Machine Learning Methods.

Authors :
Ren J
Zhou X
Guo W
Feng K
Huang T
Cai YD
Source :
BioMed research international [Biomed Res Int] 2022 Dec 28; Vol. 2022, pp. 5297235. Date of Electronic Publication: 2022 Dec 28 (Print Publication: 2022).
Publication Year :
2022

Abstract

Sarcoma, the second common type of solid tumor in children and adolescents, has a wide variety of subtypes that are often not properly diagnosed at an early stage, leading to late metastases and causing serious loss of life and property to patients and families. It exhibits a high degree of heterogeneity at the cellular, molecular, and epigenetic levels, where DNA methylation has been proposed to play a role in the diagnosis of sarcoma subtypes. Thus, this study is aimed at finding potential biomarkers at the DNA methylation level to distinguish different sarcoma subtypes. A machine learning process was designed to analyse sarcoma samples, each of which was represented by lots of methylation sites. Irrelevant sites were removed using the Boruta method, and remaining sites related to the target variables were kept for further analyses. Afterward, three feature ranking methods (LASSO, LightGBM, and MCFS) were adopted to rank these features, and six classification models were constructed by combining incremental feature selection and two classification algorithms (decision tree and random forest). Among these models, the performance of RF model was higher than that of DT model under all three ranking conditions. The specific expression of genes obtained from the annotation of highly correlated methylation site features, such as PRKAR1B, INPP5A, and GLI3, was proven to be associated with sarcoma by publications. Moreover, the quantitative rules obtained by decision tree algorithm helped us to understand the essential differences between various sarcoma types and classify sarcoma subtypes, providing a new means of clinical identification and determining new therapeutic targets.<br />Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper.<br /> (Copyright © 2022 Jingxin Ren et al.)

Details

Language :
English
ISSN :
2314-6141
Volume :
2022
Database :
MEDLINE
Journal :
BioMed research international
Publication Type :
Academic Journal
Accession number :
36619306
Full Text :
https://doi.org/10.1155/2022/5297235